

# Allistair A Abraham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8147811/publications.pdf>

Version: 2024-02-01

48  
papers

1,177  
citations

393982

19  
h-index

395343

33  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1680  
citing authors

#	ARTICLE	IF	CITATIONS
1	Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2022, 24, 249-261.	0.3	9
2	Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 174.e1-174.e5.	0.6	2
3	An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. <i>Cytotherapy</i> , 2022, 24, 385-392.	0.3	2
4	Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. <i>Cytotherapy</i> , 2022, 24, 884-891.	0.3	3
5	Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 3856.	1.0	3
6	Hematopoietic stem cell transplant referral patterns for children with sickle cell disease vary among pediatric hematologist/oncologistsâ€™ practice focus: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28861.	0.8	9
7	Gene therapy for sickle cell disease: moving from the bench to the bedside. <i>Blood</i> , 2021, 138, 932-941.	0.6	37
8	Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1018.e1-1018.e9.	0.6	7
9	Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLAR). <i>Blood</i> , 2021, 138, 3030-3030.	0.6	0
10	Adding Hydroxyurea to Chronic Transfusion for Sickle Cell Anemia Reduces Transfusion Burden: Final Results of the HAT Prospective Trial. <i>Blood</i> , 2021, 138, 2036-2036.	0.6	0
11	Disease Burden and Pre-Transplant Health-Related Quality of Life in Pediatric Sickle Cell Disease Patients Receiving Nonmyeloablative HLA-Identical Sibling Donor Transplantation. <i>Blood</i> , 2021, 138, 4073-4073.	0.6	0
12	Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLA-matched haematopoietic cell transplant for sickle cell disease. <i>British Journal of Haematology</i> , 2020, 189, 162-170.	1.2	6
13	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 333-342.	2.0	30
14	SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. <i>Blood</i> , 2020, 136, 2905-2917.	0.6	108
15	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	2.5	14
16	Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?. <i>British Journal of Haematology</i> , 2020, 189, 408-423.	1.2	29
17	Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. <i>Blood</i> , 2020, 136, 33-33.	0.6	0
18	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Engraftment in utero: it's all in the delivery. <i>Blood</i> , 2019, 134, 1889-1890.	0.6	0
20	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. <i>Blood Advances</i> , 2019, 3, 2057-2068.	2.5	27
21	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , 2019, 94, 446-454.	2.0	56
22	Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27601.	0.8	5
23	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 301-306.	2.0	27
24	Cerebral Blood Flow and Marrow Diffusion Alterations in Children with Sickle Cell Anemia after Bone Marrow Transplantation and Transfusion. <i>American Journal of Neuroradiology</i> , 2018, 39, 2132-2139.	1.2	11
25	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.	2.5	21
26	When there is no match, the game is not over: Alternative donor options for hematopoietic stem cell transplantation in sickle cell disease. <i>Seminars in Hematology</i> , 2018, 55, 94-101.	1.8	15
27	Gene Therapy: The Path Toward Becoming a Realistic Cure for Sickle Cell Disease. , 2018, , 303-328.		1
28	Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease. , 2018, , 283-302.		0
29	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1342-1349.	2.0	50
30	Lentiviral Transfer of $\beta$ -Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine $\beta$ -Thalassemia. <i>Molecular Therapy</i> , 2017, 25, 593-605.	3.7	6
31	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	1.7	43
32	Relationship between Mixed Donor Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2178-2183.	2.0	74
33	Alternative Donor/Unrelated Donor Transplants for the $\beta$ -Thalassemia and Sickle Cell Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1013, 123-153.	0.8	10
34	Homozygous $\alpha$ -thalassemia: Challenges surrounding early identification, treatment, and cure. <i>Pediatric Blood and Cancer</i> , 2017, 64, 151-155.	0.8	7
35	Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1587-1592.	2.0	58
36	Cellular therapy for sickle cell disease. <i>Cytotherapy</i> , 2016, 18, 1360-1369.	0.3	13

#	ARTICLE	IF	CITATIONS
37	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016, 128, 2561-2567.	0.6	174
38	Complex Transfusion Issues in Pediatric Hematopoietic Stem Cell Transplantation. <i>Transfusion Medicine Reviews</i> , 2016, 30, 202-208.	0.9	6
39	Increased Engraftment of Human Short Term Repopulating Hematopoietic Cells in NOD/SCID/IL2r $\beta$ null Mice by Lentiviral Expression of NUP98-HOXA10HD. <i>PLoS ONE</i> , 2016, 11, e0147059.	1.1	6
40	A Multi-Institutional Retrospective Data Analysis of Hematopoietic Cell Transplantation for Less Severe Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S95.	2.0	3
41	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2154-2159.	2.0	25
42	Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. <i>American Journal of Hematology</i> , 2015, 90, 1093-1098.	2.0	109
43	Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1285-1287.	0.8	33
44	Using Fludarabine to Reduce Exposure to Alkylating Agents in Children with Sickle Cell Disease Receiving Busulfan, Cyclophosphamide, and Antithymocyte Globulin Transplant Conditioning: Results of a Dose De-Escalation Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 900-905.	2.0	24
45	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). <i>Blood</i> , 2015, 126, 543-543.	0.6	8
46	Hematopoietic Stem Cell Transplantation for Patients with Sickle Cell Disease. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1171-1185.	0.9	50
47	Non-Myeloablative Conditioning Targeting Host Immunosuppression Is Successful in Matched Sibling Donor Stem Cell Transplantation for Hemoglobinopathies in Children. <i>Blood</i> , 2014, 124, 3873-3873.	0.6	1
48	Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2013, 60, E19-22.	0.8	34